Antheia, a pharmaceutical ingredient manufacturer, has delivered its first commercial order of thebaine to a leading pharmaceutical customer. Antheia’s first commercial delivery of thebaine is a full-scale order that will be used in the manufacturing of critical medicines. According to the company, this demonstrates its ability to successfully manufacture pharmaceutical ingredients at commercial scale and secure all necessary regulatory approvals for its biosynthetic products. 
 
“Completing our first commercial delivery of thebaine is a landmark moment for us as a company and represents a tangible step toward our mission to transform supply chains for essential medicines,” said Richard Sherwin, SVP of Commercialization at Antheia. “Today’s announcement further cements biomanufacturing’s role in the pharmaceutical industry and this is just the beginning – we look forward to fulfilling additional near-term orders and partnering with more companies to offer a more resilient and reliable supply for key starting materials (KSMs) and active pharmaceutical ingredients (APIs).” 
 
Antheia’s first product, thebaine, is a KSM for producing essential medicines used in post-surgery and severe acute pain, overdose rescue medication, and addiction treatment medications. The company has continued to produce thebaine at commercial scale with its European CDMO partner, Olon, and is actively pursuing a U.S. manufacturing strategy to serve market demand for a domestic supplier of thebaine, among other KSMs and APIs.
 
Antheia also continues to progress the development of additional products in its pipeline, including oripavine and scopolamine. The company plans to advance its commercial strategy, bringing additional products to market and onboarding global and U.S. customers.